Outlook Wealth Advisors LLC Raises Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Outlook Wealth Advisors LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 541 shares of the company’s stock after buying an additional 111 shares during the period. Outlook Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $292,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of IDXX. OFI Invest Asset Management purchased a new position in shares of IDEXX Laboratories in the third quarter worth about $25,000. Valley National Advisers Inc. raised its holdings in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Riverview Trust Co purchased a new position in IDEXX Laboratories in the 1st quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $28,000. Finally, Covestor Ltd grew its position in shares of IDEXX Laboratories by 71.8% in the third quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after purchasing an additional 28 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 2.1 %

Shares of NASDAQ:IDXX traded up $10.06 during trading on Friday, hitting $499.30. 529,834 shares of the company were exchanged, compared to its average volume of 416,262. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm’s 50 day moving average price is $531.02 and its 200-day moving average price is $510.75. The stock has a market capitalization of $41.47 billion, a P/E ratio of 49.58, a PEG ratio of 3.77 and a beta of 1.26. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same quarter in the prior year, the firm posted $2.05 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Barclays lifted their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Finally, William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Insider Buying and Selling

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is available through this link. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock worth $24,871,960 in the last quarter. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.